Skip to content
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

America Great Health AAGH

14 fiscal years on record · USD · FY2024 reported · SEC filings only
$391,743
▲ 32.9% YoY
$-719,119

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 391,743.00
Revenue, FY2024 · full 14-year series below
Revenue $M Net income $M
FY2024 · Revenue 0.4 · Net income -0.7
-2M-4M
201120142017202020232024
Compound annual growth
+55.3%
+134.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +134.9% a year over the five years to FY2024.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−184 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating -97.8% · Net -184.1%
-2000%-4000%
201120172024
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.
Gross margin86.6%
Operating margin-97.8%
Net margin-184.1%
EBITDAUSD -368,147.00

Cash & shareholders

·
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2023 · FCF -0.6
-1M-2M
201120172024

Total assetsUSD 301,817.00
EquityUSD -5.7M
CashUSD 44,056.00
Gross debtUSD 2.8M
Net debtUSD 2.8M
Current ratio0.06×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 14-year record

14 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
AAGH, 14-year financial record
Metric 20242023202220212020201920182017201620152014201320122011
Revenue $B0.00.00.00.00.00.00.00.00.00.00.0◌0.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌◌◌
EBITDA $B−0.0−0.0−0.0−0.0−0.0◌◌◌◌◌◌◌◌◌
Income tax $B◌◌◌◌0.00.00.00.00.00.0◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B◌−0.0−0.0−0.0−0.0−0.0◌◌◌◌◌◌◌◌
EPS, diluted $0.000.000.00◌0.000.000.000.000.000.000.000.000.000.00
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————————
ROE % — not applicable: negative equity——————————————
Shares out B21.1521.1421.1121.0921.0720.2420.2420.2420.2420.0619.9819.98◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 53 reconciliationsAUDITED

Reconciled in 14 of the 14 fiscal years we could check. Eight checks were skipped: the share count is not tagged before 2015. Eight checks were skipped: the balance sheet is not tagged before 2011. Four checks were skipped: revenue is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inCalifornia
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2011

Share this section

Download image